AUSTIN, Texas—Two Texas residents who suffered bone deterioration after taking the heartburn drug Nexium sued manufacturer AstraZeneca LP and its Houston district sales manager in state court Sept. 15 (Nguyen v. AstraZeneca LP).
The suit, filed in the Texas District Court, 234th Judicial District, in Houston, is unusual in alleging that Ghadeer Rafeedie, who served as AstraZeneca’s executive pharmaceutical sales representative for Houston as well as district sales manager, was negligent in failing to properly educate health care professionals about Nexium.
Since Rafeedie is a Texas resident, his inclusion in the suit could prevent AstraZeneca from removing it ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.